Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Results demonstrate the addition of preoperative iovera° treatment to a multimodal pain management protocol leads to improved outcomes during 6-week recovery period Results demonstrate the addition of preoperative iovera° treatment to a multimodal pain management protocol leads to improved outcomes during 6-week recovery period

New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty

Palo Alto Networks

Schlumberger

Spotify

Gap Inc

Iridium Communications

Kratos Defense & Security Solutions

Mimecast

Zscaler

With the trading day about halfway over, the major averages were still trying to make up their mind, with all practically flat.

Gap, Palo Alto Networks, Schlumberger, Spotify and More Monday Afternoon Analyst Upgrades and Downgrades

PARSIPPANY, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Tuesday, August 3, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021

Pacira BioSciences (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Pacira BioSciences (PCRX)

-- EXPAREL average daily sales for May 2021 were 162% of May 2020 -- -- EXPAREL momentum continues with average daily sales for May 2021 at 105% of April 2021 --

Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

How Has PCRX Performed 30 Days Post Earnings

Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal fossa) and saphenous (in adductor canal) nerve blocks in patients after lower extremity surgeries. The trial did not meet the primary endpoint of statistical significance in pain reduction from 0 to 96 hours for Exparel versus bupivacaine HCl.

Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries

-- Study did not demonstrate statistical significance for primary endpoint of pain reduction from 0 to 96 hours for EXPAREL versus bupivacaine HCl -- -- EXPAREL achieves highly statistically significant reductions in pain and total opioid consumption from 24 to 96 hours versus bupivacaine HCl (p

Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block

Composition claims for EXPAREL 200-liter process extend patent protection into 2041 Composition claims for EXPAREL 200-liter process extend patent protection into 2041

Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL

PARSIPPANY, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 RBC Capital Markets Global Healthcare Conference at 10:20 AM ET on Tuesday, May 18, 2021. Live audio of the virtual event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Pacira BioSciences reported earnings last week, and the company missed on its EPS estimate while beating its revenue estimate.

Pacira BioSciences Looks To Reverse Current Trend, And A Huge Short Position Could Help

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q1 2021 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of -10.17% and 1.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Q1 Earnings Lag Estimates

-- EXPAREL average daily sales at 115% of the prior year first quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2021.

Pacira BioSciences Reports First Quarter 2021 Financial Results and Business Update

PARSIPPANY, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Tuesday, May 4, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021

NEW YORK, April 20, 2021 /PRNewswire/ -- Spine BioPharma, LLC, a company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease, today announced a $3 million investment by Pacira Biosciences in the form of a convertible note. The investment will support the further development of Remedisc, a first-in-class therapeutic for the treatment of degenerative disc disease.

Spine BioPharma Announces Investment by Pacira Biosciences

-- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease -- PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. The investment will support the advancement of Spine BioPharma's lead candidate, Remedisc™, a first-in-class therapeutic for the treatment of degenerative disc disease. Pacira will make an additional $7 million investment predicated upon Spine BioPharma achieving certain prespecified milestones.

Pacira BioSciences Announces Investment in Spine BioPharma

Complaint challenges the American Society of Anesthesiologists for promoting biased, analytically misguided studies in its journal, on its website, and through CME activity Complaint challenges the American Society of Anesthesiologists for promoting biased, analytically misguided studies in its journal, on its website, and through CME activity

Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology

EXPAREL average daily sales at 115% of the prior year for the first quarter and 137% of the prior year for the month of March EXPAREL average daily sales at 115% of the prior year for the first quarter and 137% of the prior year for the month of March

Pacira Reports Preliminary Net Product Sales of $118.7 Million for the First Quarter of 2021

Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?

This healthcare stock just got great news from the Food and Drug Administration.

After a Label Expansion, Is This Under-the-Radar Biotech a Buy?

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

-- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over –-- Conference call tomorrow at 8:30 a.m. ET -- PARSIPPANY, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has approved the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include use in patients 6 years of age and older for single-dose infiltration to produce postsurgical local analgesia. With this approval, EXPAREL is the first and only FDA approved long-acting local analgesic for the pediatric population as young as age six.

Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric Patients

Bristol-Myers

Pfizer

BioCryst Pharmaceuticals

Marker Therapeutics Inc

ProQR Therapeutics

Rubius Therapeutics Inc

Zealand Pharma

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in solid tumors.

News for Pacira Pharmaceuticals Stock (PCRX)